Drugs / Mesothelin and Claudin 18.2 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07066995 | Apr 2025 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesothelin and Claudin 18.2 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07066995 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T (CAR T) cells” NCT07066995 ↗ |
| Route | Intravenous | “Mesothelin and Claudin 18.2 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0” NCT07066995 ↗ |
| Target | MSLN | “Mesothelin (MSLN) and Claudin 18.2 (CLDN18.2) are tumor-associated antigens overexpressed in pancreatic adenocarcinoma cells.” NCT07066995 ↗ |